… \s=b\Two hundred thirty patients with differentiated carcinoma of the thyroid gland received
… with differ¬ entiated thyroid carcinoma were treated at the University of Texas MD Anderson …

… with thyroid carcinoma is less than 1%(0.83% for women and 0.33% for men). 7 Approximately
37,200 new cases of thyroid carcinoma were diagnosed in the United States in 2009. 8 …

… Medullary thyroid carcinoma has a worse prognosis, … use in specific cancers. Many of these
compounds entered clinical trials also for locally advanced or metastatic thyroid carcinomas …

… ongoing phase II trials of BAY 43-9006 (Sorafenib) in anaplastic thyroid carcinoma and
metastatic medullary thyroid carcinoma are yet to be released. It will be important to find whether …

… Axitinib (AG-013736) is an oral, potent and selective inhibitor of VEGFRs 1, 2 and 3.
Preclinical studies demonstrated that axitinib rapidly and selectively inhibits VEGF-dependent …

This article reviews the small percentage of thyroid tumours that are not classified as classic
papillary thyroid carcinoma, follicular thyroid carcinoma, and medullary thyroid carcinoma. It …

… to the extent of surgery, use of radioactive iodine, and postoperative … facilitates the development
of a selective approach to therapy. … for management of differentiated thyroid carcinoma. …

… and RAS mutations in anaplastic carcinomas are around 50–60%… thyroid carcinomas, these
could be anaplastic carcinomas resulting from the evolution of well-differentiated carcinomas…

… A minority of thyroid cancer patients requires systemic therapy for metastatic disease. … and
used in the management of advanced thyroid cancer. The use of TKIs as a form of molecular …

… use of RRA is justifiable, or whether a more selective use of I-131 in this context is a more
reasonable approach. As has been described in this paper's present results, the more wide…